The short answer: Do not assume that glutathione injections are safe simply because the product contains the same active ingredient or is advertised as “pharmaceutical grade.” Safety depends on the indication, route of administration, finished formulation, compounding facility, sterile-process controls, endotoxin levels, concentration, impurities and storage conditions.
Glutathione intended for food or use in dietary supplements is not automatically an ingredient authorized for compounding injectable medicines. If the facility cannot provide adequate traceability information and quality documentation, postpone the injection and seek advice from an independent doctor or pharmacist. This article helps you identify risks; it does not replace a medical examination or individualized prescribing.
Are glutathione injections safe?
Safety cannot be determined solely from the name glutathione. Injection delivers a formulation directly into tissue or the circulation, so problems involving sterility, endotoxins, concentration, diluent, compatibility or storage can cause more serious systemic reactions than oral use.
The FDA has recorded symptoms including nausea, vomiting, dizziness, chills, body aches, hypotension and shortness of breath after some patients received compounded intravenous glutathione. The agency expressed concern about high endotoxin levels in some ingredient samples and warned that ingredients labeled “dietary supplement” are not suitable for compounding injectable medicines (according to FDA).
In another warning, the FDA reported adverse events after intravenous glutathione use, including cases involving food-grade ingredients and endotoxin-related concerns. This warning concerns specific sources, batches or processes; it should not be generalized into a conclusion that every glutathione product is harmful. However, the information shows that safety cannot be assessed from the active ingredient name, concentration or advertising claims alone (according to FDA).
The FDA has also raised concerns about hypersensitivity reactions, anaphylaxis and hepatotoxicity, while noting that evidence for the proposed uses remains limited. In its assessment, the FDA stated that no FDA-approved drug containing injectable or inhaled glutathione was available in the context under review. Regulations and marketing status may differ between countries, so this information does not automatically determine the legal status of a product in Vietnam (according to FDA).
Why food-grade glutathione cannot replace an injectable-drug ingredient
“Food grade” describes an intended use and a standard suitable for food or dietary supplements. It does not demonstrate that the ingredient meets the requirements for direct administration by injection. Conversely, the label “pharmaceutical grade” is not sufficient without documentation verifying the source, applicable standards and appropriate quality controls.
Ingredients used in injectable medicines must be controlled within a system appropriate for sterile medicines, covering the supply source, manufacturing conditions, risks of microbial contamination, particulate matter, endotoxins and impurities, as well as stability, packaging, storage and batch-level traceability. For sterile medicines, the WHO emphasizes control of microbial contamination, particulate matter and endotoxins. Water used for compounding and the finished product must also be controlled using appropriate methods that have been validated or are specified in the applicable pharmacopoeia (according to who.int).
A COA (Certificate of Analysis) does not by itself prove that an injectable medicine is safe. A COA is useful for reference only when it corresponds to the correct batch number, comes from a reliable issuer and covers appropriate specifications. The compounding facility must also control the supplier, compounding process, environment, personnel, storage and release; it cannot rely solely on a final test result.
How to check the ingredient and formulation before an injection
Patients cannot confirm sterility or endotoxin levels simply by looking at a vial. Use the table below to ask the doctor, pharmacist or facility to explain the product and provide documentation. If the information is unavailable, that is a reason to postpone the injection—not a reason to make your own assumptions.
| What to check | What should be present | Warning signs |
|---|---|---|
| Intended use stated on the label | Clearly identifies the ingredient as a pharmaceutical raw material or active pharmaceutical ingredient, or states an intended use compatible with manufacturing an injectable formulation, as supported by the relevant documentation and regulations. | States “dietary supplement,” “food grade,” “nutritional use,” “for oral use” or “not for pharmaceutical use.” |
| Manufacturer and traceability | The original manufacturer’s name and address, country of manufacture, batch number, manufacturing date, expiry date, storage conditions and distributor are clearly identified. | Only the seller’s name is provided; there is a replacement label; the original manufacturer cannot be identified; or the batch number does not match across the documents. |
| Quality standards | The applicable standard, specifications, acceptance limits and test methods appropriate for a pharmaceutical ingredient are identified. | It states only “99% purity” or “pharmaceutical grade” without specifying the standard, method or limits. |
| Sterility and endotoxins | The facility can demonstrate control of sterility and endotoxins at a level appropriate for the injectable formulation. | It treats pure powder or an unopened vial as proof of sterility, or provides no information about endotoxins. |
| Certificate of Analysis (COA) | The COA corresponds to the correct batch number, identifies its issuer and test date, reports relevant test results, and can be explained by the facility. | The COA is an unverifiable scan, has no batch number or issuer, or reports only the glutathione content. |
| Finished formulation | The label clearly states the ingredients, concentration, volume, batch number, expiry date, storage conditions, route of administration and responsible facility. | The vial is unlabeled, has a handwritten label, has no expiry date, does not state the route of administration, or was divided from a larger container that cannot be traced. |
| Facility administering the injection | The injection is administered at a healthcare facility or a legally operating compounding facility with a designated professional in charge and procedures for post-injection monitoring and treatment. | The injection is given at a spa or in a facility with an unclear scope of operations, bundled with a beauty package, or requires the user to purchase the medicine independently without documentation. |
In Vietnam, a pharmaceutical ingredient is a component used to make a medicine, including an active pharmaceutical ingredient, medicinal material, excipient or capsule shell. The quality of medicines and pharmaceutical ingredients must be linked to applicable quality standards, specifications, quality limits, test methods and related regulatory requirements. Therefore, ask what this ingredient is intended to be used for, which facility is responsible for the injectable formulation, and which standard is used to control it, rather than simply asking whether it is “genuine” or “premium” (according to thuvienphapluat.vn).
Seven questions to ask before agreeing to an injection

- Is this a finished medicine or a compounded preparation? If it is compounded, which facility prepared it, and who is professionally responsible?
- Which company manufactures the glutathione? Ask for the original manufacturer’s name, country of manufacture and batch number.
- What grade is the ingredient labeled as, and which route of administration is it intended for? If the label states that the product is for food use, for oral use, or not for pharmaceutical use, it should not be injected.
- Which quality attributes have been tested in the preparation? Ask specifically about assay, impurities, sterility, bacterial endotoxins, stability, and storage conditions.
- Does the certificate of analysis (COA) match the lot number on the vial? A COA for a different lot does not demonstrate the quality of the vial you are about to use.
- What condition is the injection intended to treat, and how strong is the evidence for its benefit? Claims about antioxidant effects, skin lightening, or “detoxification” do not mean that the treatment has an indication recognized by a regulatory authority.
- Where would the facility manage a reaction if one occurred? The facility should have qualified personnel, appropriate equipment, and procedures for managing anaphylaxis, hypotension, breathing difficulty, and systemic reactions.
If the facility responds only with phrases such as “imported product,” “international standard,” “99% pure,” or “we have injected many people,” but cannot provide traceability information and applicable standards, you should postpone the decision.
Danger signs after injection
A reaction after injection may be related to allergy or anaphylaxis, an incorrect concentration, contamination, bacterial endotoxins, impurities, drug interactions, or an underlying condition. The cause cannot be determined from a single symptom alone.
Call your local emergency number or go to an emergency department immediately if you develop shortness of breath, wheezing, swelling of the lips or tongue, rapidly spreading hives, chest pain, altered consciousness, fainting, low blood pressure, high fever, severe chills, repeated vomiting, or a severe headache. Symptoms such as fever, chills, muscle pain, nausea, vomiting, and hypotension have been described by the FDA in a warning about injectable glutathione products with high bacterial endotoxin levels.
While waiting to be assessed, do not inject another dose or self-medicate in an attempt to delay emergency care. Bring the vial, box, label photographs, lot number, and COA if available; record the time of injection, the dose if known, and when the symptoms began.
What to do if you have already been injected with a product of uncertain origin
- Do not continue using any remaining vial or lot until it has been assessed by a doctor or pharmacist.
- Keep the packaging and vial intact; do not discard them unless instructed to do so, because the lot information may be needed for traceability.
- Do not assume that the product is safe simply because you have no symptoms. If you develop shortness of breath, dizziness or faintness, fever, chills, a rash, or unusual pain, seek medical attention promptly; severe symptoms require emergency care.
- Ask the facility to provide the records, including the product name, manufacturer, lot number, compounding facility, responsible person, and storage conditions.
- Tell the clinician about every product you have received, rather than waiting to see whether the symptoms resolve on their own.
A safer decision-making principle
Glutathione should not be judged safe solely on the basis of the active ingredient’s name, its concentration, or advertising claims. Food-grade raw material is not a substitute for material intended for injectable medicines; the phrase “pharmaceutical grade” is also insufficient without the manufacturer, lot number, applicable specifications, and evidence of appropriate quality control.
Before agreeing to an injection, verify at least four categories of information: origin, intended use, sterility and endotoxin controls, and the responsibility of the facility performing the procedure. If these details cannot be verified, the safer choice is to postpone the injection and seek an opinion from an independent doctor or pharmacist.
Reference source
- FDA reminds compounders not to use dietary supplement grade glutathione for injectables
- FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables
- FDA conclusion on Safety
- Optimal Balance Pharmacy Issues Voluntary Nationwide Recall of Certain Lots of Compounded Glutathione 200 mg/mL Multi-Dose Vials Due to Elevated Endotoxin Levels
- TRS 1044 – Annex 2: WHO good manufacturing practices for sterile pharmaceutical products
- Văn bản hợp nhất 07/VBHN-BYT 2024 Thông tư chất lượng thuốc nguyên liệu làm thuốc

